Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's product candidates include EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development programs comprise KPI-285/KPI-286, a receptor tyrosine kinase inhibitor program for the treatment of various retinal diseases; SEGRM program, a novel class of compounds designed to regulate gene expression through the transrepression pathway while avoiding the transactivation pathway; and surface targeted steroid program (KPI-333), a new chemical entity as a topical steroid that targets the ocular surface. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Watertown, Massachusetts.
IPO Year: 2017
Exchange: NASDAQ
Website: kalarx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/11/2025 | $12.00 | Buy | Ladenburg Thalmann |
| 3/30/2022 | Neutral → Underweight | JP Morgan | |
| 8/6/2021 | $14.00 → $11.00 | Buy | HC Wainwright & Co. |
| 8/6/2021 | Overweight → Neutral | JP Morgan |
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - KALA BIO, Inc. (0001479419) (Issuer)
4 - KALA BIO, Inc. (0001479419) (Issuer)
4 - KALA BIO, Inc. (0001479419) (Issuer)
4 - KALA BIO, Inc. (0001479419) (Issuer)
4 - KALA BIO, Inc. (0001479419) (Issuer)
4 - KALA BIO, Inc. (0001479419) (Issuer)
4 - KALA BIO, Inc. (0001479419) (Issuer)
4 - KALA BIO, Inc. (0001479419) (Issuer)
4 - KALA BIO, Inc. (0001479419) (Issuer)
4 - KALA BIO, Inc. (0001479419) (Issuer)
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - KALA BIO, Inc. (0001479419) (Issuer)
10-Q - KALA BIO, Inc. (0001479419) (Filer)
8-K - KALA BIO, Inc. (0001479419) (Filer)
8-K - KALA BIO, Inc. (0001479419) (Filer)
144 - KALA BIO, Inc. (0001479419) (Subject)
144 - KALA BIO, Inc. (0001479419) (Subject)
144 - KALA BIO, Inc. (0001479419) (Subject)
10-Q - KALA BIO, Inc. (0001479419) (Filer)
8-K - KALA BIO, Inc. (0001479419) (Filer)
SCHEDULE 13G/A - KALA BIO, Inc. (0001479419) (Subject)
8-K - KALA BIO, Inc. (0001479419) (Filer)
Fastest customizable press release news feed in the world
-- Completed patient enrollment in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED); topline data expected at the end of September 2025 -- -- Cash resources of $31.9 million as of June 30, 2025, expected to fund operations into 1Q 2026 -- ARLINGTON, Mass., Aug. 08, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today reported financial results for the second quarter ended June 30, 2025 and provided a corporate update. "The second quarter of 2025 was a pivotal period for KALA, marked
ARLINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that members of management will present at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference being held virtually on Wednesday, August 13, 2025. A pre-recorded presentation will be made available beginning on Wednesday, August 13, 2025 at 7:00 a.m. ET. KALA management will also participate in a panel discussion titled "Novel Treatments for Front-of-the-Eye Indications" on Wednesday, August 13, 2025 at 1:00 p.m. ET
-- Topline results from the CHASE trial expected by end of Q3 2025 -- -- Potential for CHASE to serve as a pivotal trial in support of a Biologics License Application (BLA) submission, contingent on positive results -- ARLINGTON, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced the completion of patient enrollment in the CHASE (Corneal Healing After SEcretome therapy) Phase 2b clinical trial evaluating KPI-012, a human mesenchymal stem cell secretome (MCS-S), for the treatment of pers
ARLINGTON, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that the Company will host a webcast event with Key Opinion Leaders (KOLs) to discuss the potential of KPI-012 for the treatment of persistent corneal epithelial defect (PCED). The event will take place on Wednesday, July 16, 2025, at 4:00 p.m. ET. The webcast event will feature presentations from: Francis Mah, M.D., Director of Cornea and External Disease & Co-Director, Refractive Surgery at Scripps Clinic Medical Gr
ARLINGTON, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that members of management will present at the Jefferies Global Healthcare Conference being held in New York, NY on Thursday, June 5, 2025 at 1:25 p.m. ET. Management will also be available for one-on-one meetings on Thursday, June 5, 2025. To access the webcast and subsequent archived recording of the presentation, please visit the "Presentations" section of the KALA website at www.kalarx.com. About KALA BIO, Inc. KALA is a
-- Ongoing patient enrollment in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED); topline data anticipated in 3Q 2025 -- -- Cash resources of $42.2 million as of March 31, 2025, expected to fund operations into 1Q 2026 -- ARLINGTON, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today reported financial results for the first quarter ended March 31, 2025 and provided a corporate update. "This year, our top priority is advancing the development of KPI-012 to
-- Randomized 87 patients to date in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED) -- -- Continuing enrollment into 2Q25; currently targeting topline data in 3Q25 -- -- Raised $10.75 million in private placement financing with participation from SR One, Cormorant Asset Management, Woodline Partners and another life sciences-focused investor -- -- Cash resources of $51.2 million as of December 31, 2024, expected to fund operations into 1Q 2026 -- ARLINGTON, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies
ARLINGTON, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that members of management will present at the TD Cowen 45th Annual Health Care Conference being held in Boston, MA on Wednesday, March 5, 2025 at 11:50 a.m. ET. Management will also be available for one-on-one meetings on Wednesday, March 5, 2025. To access the webcast and subsequent archived recording of the presentation, please visit the "Presentations" section of the KALA website at www.kalarx.com. About KALA BIO, Inc. K
ARLINGTON, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced the resignation of Chief Executive Officer (CEO) Mark Iwicki, and the appointment of Todd Bazemore, KALA's President and Chief Operating Officer, as interim CEO, effective immediately. Mr. Iwicki will continue to serve as Chair of the Board of Directors of KALA following the transition. Mr. Bazemore has served as KALA's President since December 2021 and as KALA's Chief Operating Officer since November 2017. Mr. Iwicki stated,
ARLINGTON, Mass., Dec. 30, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors for the sale, in a private placement, of shares of its common stock and shares of its Series I Convertible Non-Redeemable Preferred Stock (the "Series I Preferred Stock"), for aggregate gross proceeds of approximately $10.75 million, before deducting offering expenses. The private placement included participation
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Ladenburg Thalmann initiated coverage of KALA BIO with a rating of Buy and set a new price target of $12.00
JP Morgan downgraded Kala Pharmaceuticals from Neutral to Underweight
HC Wainwright & Co. reiterated coverage of Kala Pharmaceuticals with a rating of Buy and set a new price target of $11.00 from $14.00 previously
JP Morgan downgraded Kala Pharmaceuticals from Overweight to Neutral
HC Wainwright & Co. reiterated coverage of Kala Pharmaceuticals with a rating of Buy and set a new price target of $14.00 from $16.00 previously
HC Wainwright resumed coverage of Kala Pharmaceuticals with a rating of Buy and set a new price target of $17.00
Live Leadership Updates
ARLINGTON, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced the resignation of Chief Executive Officer (CEO) Mark Iwicki, and the appointment of Todd Bazemore, KALA's President and Chief Operating Officer, as interim CEO, effective immediately. Mr. Iwicki will continue to serve as Chair of the Board of Directors of KALA following the transition. Mr. Bazemore has served as KALA's President since December 2021 and as KALA's Chief Operating Officer since November 2017. Mr. Iwicki stated,
-- Announced positive data from initial safety portion of CHASE Phase 2b clinical trial of KPI-012; now enrolling primary safety and efficacy portion of trial, with topline data targeted in 1Q 2024 ---- Received FDA Fast Track designation for KPI-012 for the treatment of PCED ---- Strengthened clinical R&D team with appointment of Dr. Francis Mah as Chief Medical Advisor – -- Awarded $15 million grant from CIRM to support the KPI-012 PCED program -- ARLINGTON, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and sever
ARLINGTON, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced the appointment of Francis Mah, M.D., as Chief Medical Advisor. In this newly established role, Dr. Mah will provide support for Kala's clinical development and medical activities and will play a key role in interactions with eye care professionals. Dr. Mah will serve in this role on a part time basis while continuing his ongoing position as Director of Cornea and External Disease and the Co-Director, Refractive Su
-- Planning to Initiate Phase 2/3 Trial of KPI-012 for Persistent Corneal Epithelial Defect (PCED) in 4Q 2022; Topline Data Expected in 1Q 2024 ---- Ended Quarter with $52.4 million in Cash; Sufficient for Funding Operations into 2Q 2024 -- ARLINGTON, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update. "We continue to advance our proprietary mesenchymal stem cell secretome (MSC-S) platform a
ARLINGTON, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA) ("Kala" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today announced the appointment of Marjan Farid, M.D., to its Board of Directors. Dr. Farid, who is currently Professor of Clinical Ophthalmology, Director of Cornea, Refractive & Cataract Surgery, and Vice Chair of Ophthalmic Faculty at the Gavin Herbert Eye Institute, University of California Irvine (UCI), founded the Severe Ocular Surface Disease Center at UCI and is an industry leader in the care and treatment of
WATERTOWN, Mass., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced the appointment of C. Daniel Myers to its Board of Directors. Mr. Myers, who has more than 35 years of ophthalmic pharmaceutical experience, will serve as a Class III director, and join both the Compensation and Nominating and Corporate Governance Committees. "We are very pleased to welcome Dan to our Board of Directors," said Mark Iwicki, Chairman, President and Chief Executive Officer of Kala Pharmaceuticals. "Dan has an
This live feed shows all institutional transactions in real time.
SC 13G - KALA BIO, Inc. (0001479419) (Subject)
SC 13D - KALA BIO, Inc. (0001479419) (Subject)
SC 13D - KALA BIO, Inc. (0001479419) (Subject)
SC 13G - KALA BIO, Inc. (0001479419) (Subject)
SC 13G/A - KALA BIO, Inc. (0001479419) (Subject)
SC 13G/A - KALA BIO, Inc. (0001479419) (Subject)
SC 13G/A - KALA BIO, Inc. (0001479419) (Subject)
SC 13D/A - KALA BIO, Inc. (0001479419) (Subject)
SC 13G - Kala Pharmaceuticals, Inc. (0001479419) (Subject)
SC 13G - Kala Pharmaceuticals, Inc. (0001479419) (Subject)
Live finance-specific insights
ARLINGTON, Mass., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA) ("Kala" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series D Preferred Stock, par value $0.001 per share, for each outstanding share of the Company's common stock held of record as of 5:00 p.m. Eastern Time on August 29, 2022. The shares of Series D Preferred Stock will be distributed to such recipients at 5:00 p.m. Eastern Time on August 30, 2022. The
-- Plan to Initiate Phase 2/3 Trial of KPI-012 for Persistent Corneal Epithelial Defect (PCED) in 4Q 2022; Topline Data Expected in 1Q 2024 ---- Received $60M Upfront Payment from Sale of EYSUVIS® and INVELTYS® to Alcon Inc. and Significantly Reduced Operating Expenses, Extending Cash Runway into 2Q 2024 -- -- Conference Call and Webcast at 8:00 a.m. ET -- ARLINGTON, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today reported financial results for the second quarter ended June 30, 2022 and prov
ARLINGTON, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today announced that it will report second quarter 2022 financial results on Thursday, August 11, 2022. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 8:00 a.m. ET. The dial-in number to access the conference call is 800-715-9871 using the conference ID 9372651. To access a live webcast and subsequent archived recording of the call, please visit the "Presentations" se
- Expanded Coverage for EYSUVIS® to 92% of Total Commercial Lives and 30% of All Medicare Lives - - Achieved 18% EYSUVIS Prescription Growth in 1Q 2022 - - Presented KPI-012 Phase 1b Clinical Data at ARVO; Initiation of Phase 2/3 Clinical Trial in PCED Expected 4Q 2022 - - Conference Call and Webcast at 8:00 a.m. ET - ARLINGTON, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.
ARLINGTON, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will report first quarter 2022 financial results on Monday, May 16, 2022. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 8:00 a.m. ET. The dial-in numbers to access this conference call are 866-300-4091 (domestic) or 703-736-7433 (international) using the conference ID 6384677. To access a live webcast and subsequent archived recording of the call, pl
-- Achieved $11.2 Million in Net Revenue in 2021 ---- Expanded Coverage for EYSUVIS® to 118 Million Commercial Lives and 7.1 Million Medicare Lives ---- KPI-012 Phase 1b Clinical Data Accepted for Presentation at ARVO; Initiation of Phase 2/3 Clinical Trial of KPI-012 expected in 4Q 2022 ---- Conference Call and Webcast at 8:00 a.m. ET -- ARLINGTON, Mass., March 29, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided
ARLINGTON, Mass., March 23, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will report fourth quarter and full year 2021 financial results on Tuesday, March 29, 2022. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 8:00 a.m. ET. The dial-in numbers to access the conference call are 866-300-4091 (domestic) or 703-736-7433 (international) using the conference ID 7368936. To access a live webcast and subsequent archived record
-- Achieved $3.1 Million in Net Revenue in 3Q 2021 ---- EYSUVIS® Prescriptions Increased by 19% Compared to 2Q 2021-- Expanding Clinical-Stage Pipeline Through Acquisition of Combangio ---- Conference Call and Webcast at 10:30 a.m. ET -- WATERTOWN, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update. "We have made progress toward our goal of providing patients and physicians with a portfolio of i
-- KPI-012 is a novel secretome with a multifactorial mechanism of action for development in PCED and other orphan ocular surface diseases driven by impaired corneal healing ---- KPI-012 demonstrated positive safety and efficacy results in PCED Phase 1b clinical trial ---- Kala expects to initiate Phase 2/3 trial in 3Q 2022 ----Mark S. Blumenkranz, M.D., Professor Emeritus in the Department of Ophthalmology at Stanford University, appointed to Kala's Board of Directors ---- Management to host conference call at 10:30 a.m. ET today -- WATERTOWN, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the d
WATERTOWN, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it has changed the time of its previously scheduled financial results conference call and live audio webcast. The Company will now report its third quarter 2021 financial results and provide a business update on Monday, November 15th at 10:30 am. ET. The dial-in numbers to access the conference call are 866-300-4091 (domestic) or 703-736-7433 (international) using the conference ID 7298039. To access a live webcast and subse